Archimedes Pharma is an international specialty pharmaceutical company providing novel and advanced treatments to address unmet needs for people living with serious or life-threatening chronic and debilitating illnesses. Marketing a diverse portfolio of specialty products focused on the oncology, pain, and critical care sectors, Archimedes Pharma has operations in Europe. Founded in 2004, Archimedes Pharma initially acquired a range of specialty products and technologies together with a commercial pharmaceutical platform to establish itself in the European market. Since then the company has expanded its operations to include the in-house development of products based on its proprietary drug delivery technologies. In 2010, Archimedes Pharma attracted significant additional investment to further the company’s growth strategies and build an experienced leadership team, raising approximately $100 million in capital - the largest amount raised by a private European biopharmaceutical company in recent years. Archimedes Pharma has a strong commitment to patients and its customers. By providing novel and technologically advanced therapies, Archimedes Pharma looks to improve current therapeutic approaches and enhance care to patients.